(ANTX) (ANTX) News Today Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrendsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 13 at 9:13 PM | markets.businessinsider.comMarket Perform Rating Maintained for AN2 Therapeutics Amidst Pipeline Potential and Phase 2 SetbacksSeptember 12, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: AN2 Therapeutics, Inc. (ANTX) and Roche Holding AG (OtherRHHVF)August 13, 2024 | markets.businessinsider.comANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comWhy Is AN2 Therapeutics (ANTX) Stock Down 35% Today?May 14, 2024 | businesswire.comAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsApril 9, 2024 | markets.businessinsider.comMaintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial UncertaintiesApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation ProspectsMarch 29, 2024 | markets.businessinsider.comANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023March 28, 2024 | businesswire.comAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXFebruary 17, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXFebruary 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXFebruary 14, 2024 | realmoney.thestreet.comAN2 Therapeutics just downgraded at Evercore ISI, here's whyFebruary 13, 2024 | reuters.comAN2 Therapeutics shares fall after pausing lung disease study enrollmentFebruary 13, 2024 | realmoney.thestreet.comAN2 Therapeutics just downgraded at Leerink, here's whyFebruary 12, 2024 | markets.businessinsider.comAN2 Therapeutics, Inc. (ANTX) was downgraded to a Hold Rating at JMP SecuritiesFebruary 12, 2024 | marketwatch.comAN2 Therapeutics Shares Drop 73% After Pausing Enrollment for Epetraborole TrialFebruary 12, 2024 | realmoney.thestreet.comJMP Securities gets more bearish on AN2 Therapeutics, downgrades sharesFebruary 12, 2024 | realmoney.thestreet.comAN2 Therapeutics just downgraded at Oppenheimer, here's whyFebruary 12, 2024 | reuters.comAN2 Therapeutics to pause lung disease study enrollmentFebruary 12, 2024 | markets.businessinsider.comAN2 Therapeutics Stock Plummets On Decision To Pause Enrollment In Epetraborole Phase 2/3 TrialFebruary 12, 2024 | finance.yahoo.comAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseJanuary 12, 2024 | finance.yahoo.comAN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 SharesJanuary 10, 2024 | finance.yahoo.comRecent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's WhyDecember 16, 2023 | markets.businessinsider.comThese Biotech Stocks Caught Our Attention - Did You Notice?November 12, 2023 | finance.yahoo.comOne AN2 Therapeutics Insider Raised Their Stake In The Previous YearNovember 9, 2023 | finance.yahoo.comAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsNovember 6, 2023 | finance.yahoo.comAN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's WhyOctober 18, 2023 | finance.yahoo.comAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseOctober 17, 2023 | markets.businessinsider.comPromising Outlook for AN2 Therapeutics, Inc.: Buy Rating Conferred Amid Anticipated Ph.2 Results and Encouraging Epetraborole DevelopmentsOctober 16, 2023 | finance.yahoo.comAN2 Therapeutics, Inc. (NASDAQ:ANTX) stock most popular amongst individual investors who own 29%, while private equity firms hold 27%October 11, 2023 | finance.yahoo.comAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023October 4, 2023 | msn.comWhy Wall Street investors are freaking outSeptember 27, 2023 | finance.yahoo.comIs Adagene (ADAG) Outperforming Other Medical Stocks This Year?September 26, 2023 | finance.yahoo.comAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and MalariaSeptember 13, 2023 | finance.yahoo.comAN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung DiseaseSeptember 11, 2023 | finance.yahoo.comHas AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?August 25, 2023 | insidermonkey.comHedge Fund and Insider Trading News: George Soros, Ray Dalio, Crispin Odey, Three Arrows Capital (3AC), Cassava Sciences Inc (SAVA), AN2 Therapeutics, Inc. (ANTX), and MoreAugust 16, 2023 | finance.yahoo.comAN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common StockAugust 10, 2023 | finance.yahoo.comAN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsJune 14, 2023 | finance.yahoo.comCompanies Like AN2 Therapeutics (NASDAQ:ANTX) Are In A Position To Invest In GrowthMay 25, 2023 | finance.yahoo.comAN2 Therapeutics to Present at Jefferies Healthcare ConferenceMay 11, 2023 | finance.yahoo.comAN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsMay 9, 2023 | finance.yahoo.comAN2 Therapeutics, Inc.'s (NASDAQ:ANTX) market cap dropped US$43m last week; individual investors who hold 33% were hit as were institutionsMay 1, 2023 | finance.yahoo.comAN2 Therapeutics to Present at JMP Securities Life Sciences ConferenceApril 26, 2023 | msn.comLina Hidalgo photographed by the legendary Annie Leibovitz for Vogue magazineMarch 30, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on AN2 Therapeutics, Inc. (ANTX)March 29, 2023 | finance.yahoo.comAN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Coin Could 10x FASTER Than Bitcoin (Ad)A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold. Click here to review my research and unique strategy to score potential profits from this under-the- ANTX Media Mentions By Week ANTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANTX News Sentiment▼0.000.68▲Average Medical News Sentiment ANTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANTX Articles This Week▼20▲ANTX Articles Average Week Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PBYI News Today ACET News Today VERU News Today RMTI News Today IVA News Today ALXO News Today ASRT News Today ASMB News Today FBLG News Today VSTM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANTX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ANTX) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ANTX) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANTX Stock Alerts